- Home
- UTHR vs SUI Comparison
UTHR vs SUI Comparison
Compare UTHR & SUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- SUI
- Stock Information
- Founded
- UTHR 1996
- SUI 1975
- Country
- UTHR United States
- SUI United States
- Employees
- UTHR N/A
- SUI N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- SUI Real Estate Investment Trusts
- Sector
- UTHR Health Care
- SUI Real Estate
- Exchange
- UTHR Nasdaq
- SUI Nasdaq
- Market Cap
- UTHR 14.4B
- SUI 16.0B
- IPO Year
- UTHR 1999
- SUI 1993
- Fundamental
- Price
- UTHR $291.72
- SUI $125.96
- Analyst Decision
- UTHR Buy
- SUI Buy
- Analyst Count
- UTHR 13
- SUI 12
- Target Price
- UTHR $393.08
- SUI $138.33
- AVG Volume (30 Days)
- UTHR 690.9K
- SUI 812.0K
- Earning Date
- UTHR 07-30-2025
- SUI 07-30-2025
- Dividend Yield
- UTHR N/A
- SUI 6.24%
- EPS Growth
- UTHR 18.86
- SUI N/A
- EPS
- UTHR 25.10
- SUI 0.58
- Revenue
- UTHR $2,994,100,000.00
- SUI $3,193,300,000.00
- Revenue This Year
- UTHR $14.30
- SUI N/A
- Revenue Next Year
- UTHR $6.32
- SUI $2.20
- P/E Ratio
- UTHR $11.62
- SUI $155.15
- Revenue Growth
- UTHR 19.84
- SUI 6.74
- 52 Week Low
- UTHR $266.98
- SUI $109.22
- 52 Week High
- UTHR $417.82
- SUI $147.83
- Technical
- Relative Strength Index (RSI)
- UTHR 43.35
- SUI 55.39
- Support Level
- UTHR $281.97
- SUI $122.66
- Resistance Level
- UTHR $329.85
- SUI $128.66
- Average True Range (ATR)
- UTHR 9.11
- SUI 2.56
- MACD
- UTHR -3.44
- SUI 0.16
- Stochastic Oscillator
- UTHR 29.04
- SUI 64.00
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About SUI Sun Communities Inc.
Sun Communities is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently owns a portfolio of 645 properties, which includes 341 manufactured housing communities, 166 residential vehicle communities, and 138 marina properties. Sun targets owning properties that are desirable as second homes or vacation properties with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.